Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis.
Mathias MaagaardEmil Eik NielsenNaqash Javaid SethiNing LiangSi-Hong YangChristian GluudJanus Christian JakobsenPublished in: BMJ evidence-based medicine (2021)
High certainty evidence shows that ivabradine does not seem to affect the risks of all-cause mortality and cardiovascular mortality. The effects on quality of life were small and possibly without relevance to patients on the KCCQ and were very uncertain for the MLWHFQ. The effects on serious adverse events, myocardial infarction and hospitalisation are uncertain. Ivabradine seems to increase the risk of atrial fibrillation, bradycardia and non-serious adverse events.PROSPERO registration number: CRD42018112082.
Keyphrases
- heart rate
- end stage renal disease
- atrial fibrillation
- ejection fraction
- heart failure
- healthcare
- newly diagnosed
- chronic kidney disease
- clinical trial
- palliative care
- peritoneal dialysis
- blood pressure
- left ventricular
- study protocol
- prognostic factors
- type diabetes
- risk factors
- patient reported outcomes
- acute coronary syndrome
- climate change
- risk assessment
- phase iii
- coronary artery disease